Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in some device units. If a device with a blocked guidewire lumen were to be used during the procedure, the device would not be positioned correctly and hemorrhage would not be controlled. This would delay life-saving treatment, which may result in immediate and serious adverse health consequences, including death.

September 26, 2017 — The one-year results of the SENTRY clinical trial were presented by principal investigator Michael ...

BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during the “Heart Failure: The Big Target for CV Regenerative Therapy State of the Field” session at the Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine, Sept. 15-16 in Houston. As an invited faculty member for the meeting, Professor of Cardiovascular Medicine at the University of Florida and study co-national principal investigator Carl Pepine, M.D., presented the design.

The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and the first in Canada to be exclusively dedicated to cardiac surgery. "The development of robotic cardiac surgery plays a major role in the expansion of minimally invasive surgery, whose purpose is to minimize the trauma endured by the body by reducing the incision size, for instance", according to the surgical team counting among its members Michel Pellerin, M.D., and Denis Bouchard, M.D., the two cardiac surgeons who performed the first robotic mitral intervention last April. "This new technology will improve the patients' quality of life and allow for a faster return to daily activity, among other benefits", they continued.

September 21, 2017 — Fujitsu announced that the University of Tokyo recently used heart simulator viewers with ...

MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study were presented at the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting, Sept. 16-19 in Dallas. PIONEER-HCM was a study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients.

September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was ...

September 20, 2017 — Catheter ablation to treat an irregular heartbeat, which limits or eliminates patients’ exposure to ...